Anti-Mouse CD103 Antibody (M290) 

Anti-Mouse CD103 Antibody (M290) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD103. Anti-Mouse CD103 Antibody (M290) can neutralize CD103. Anti-Mouse CD103 Antibody (M290) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as B16.gp33 tumor, colitis and diabetes^[1][2][3].

Rat IgG2a kappa

Rat IgG2a kappa, Isotype Control

Mouse

CD103

Anti-Mouse CD103 Antibody (M290) (M290-MC-MMAF, N290 conjugated with Maleimidocaproyl-monomethyl auristatin F) (0-10 μg/mL, 48 h) reduces and inhibits the proliferation of CD8⁺ T cells in splenic lymphocytes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse CD103 Antibody (M290) (250 μg, i.p., every fifth day starting 1 day before adoptive transfer of either VHL-KO T cells) results in effective blockade of CD103 expression on VHL-KO TILs, which translated into loss of tumor control in B16.gp33 tumor mice^[1].
Anti-Mouse CD103 Antibody (M290) (1 mg at 1 day after T cell reconstitution and 0.5 mg twice a week for 8 weeks, i.p.) abrogates suppression of colitis by CD4⁺CD45RB^low T cells in colitis mice models^[2].
Anti-Mouse CD103 Antibody (M290) (M290-MC-MMAF, M290 conjugated with Maleimidocaproyl-monomethyl auristatin F) (3 mg/kg, i.p., at days 1, 3 and 5) promotes pancreatic islet allograft survival in diabetic C57BL/6 mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

16407  [NCBI]

Q60677

in vivo CD103 neutralization; Immunofluorescence; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse CD103 Antibody (M290)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liikanen I, et al. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest. 2021 Apr 1;131(7):e143729.  [Content Brief]

  [2]. Annacker O, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med. 2005 Oct 17;202(8):1051-61.  [Content Brief]

  [3]. Xue D, et al. An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice. Cell Death Dis. 2019 Sep 30;10(10):735.  [Content Brief]